Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

12.42USD
18 Oct 2018
Change (% chg)

$-0.51 (-3.94%)
Prev Close
$12.93
Open
$12.91
Day's High
$13.03
Day's Low
$12.04
Volume
44,130
Avg. Vol
128,589
52-wk High
$16.70
52-wk Low
$5.60

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  ALDX.OQ Industry Sector
P/E (TTM): -- 85.83 33.69
EPS (TTM): -1.47 -- --
ROI: -72.27 0.58 14.30
ROE: -75.02 1.62 16.03

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

10 May 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

24 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $139.50 +0.04
Novartis AG (NOVN.S) CHF85.88 +1.60
Pfizer Inc. (PFE.N) $44.00 -0.57
AbbVie Inc (ABBV.N) $89.90 -2.37
Amgen, Inc. (AMGN.OQ) $202.72 -0.05
Bristol-Myers Squibb Co (BMY.N) $55.98 -2.92
Bristol-Myers Squibb Co (BMYMP.PK) $1,050.20 --
UCB SA (UCB.BR) €73.08 --

Earnings vs. Estimates